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Abstract: This review summarizes the long-term clinical outcomes associated with β-agonist 
and anticholinergic bronchodilator use in patients with chronic obstructive pulmonary disease 
(COPD). Pooled data from randomized placebo-controlled trials of at least three months dura-
tion were used to evaluate the risk for COPD hospitalizations, respiratory mortality, and total 
mortality. The results show that anticholinergic use is associated with a 30% reduction in COPD 
hospitalizations, a 70% reduction in respiratory mortality, and without a signiﬁ  cant effect on 
total mortality. In contrast, β-agonist use had no effect on COPD hospitalizations and was 
associated with a two-fold increased risk for respiratory death compared with placebo. When 
the two bronchodilators were directly compared with each other, β-agonists were associated 
with a two-fold increased risk for COPD hospitalization and a ﬁ  ve-fold increased risk for total 
mortality compared with anticholinergics. When β-agonists were added to either anticholinergic 
use or inhaled corticosteroid use alone, there was no signiﬁ  cant improvement in any long-term 
clinical outcome. These results indicate that anticholinergics should be the bronchodilator of 
choice in COPD, while β-agonists may be associated with poorer disease control. 
Keywords: chronic obstructive pulmonary disease, COPD, adrenergic beta-agonists, cholinergic 
antagonists, bronchodilator, systematic review, clinical outcomes, mortality.
Long-term clinical outcomes in COPD
Chronic obstructive pulmonary disease (COPD) is characterized by partially revers-
ible chronic airﬂ  ow obstruction, caused by inﬂ  ammatory reactions in the airways and 
lung parenchyma to inhaled toxins such as tobacco smoke (Celli and MacNee 2004). 
The airﬂ  ow obstruction is progressive over time, and is often accompanied by some 
degree of airway hyperreactivity, which may be partially reversible (ATS 1995). Acute 
exacerbations of COPD occur, deﬁ  ned loosely as an episode of increased dyspnea, 
cough, and sputum production (McCrory et al 2001). Exacerbations severe enough to 
require hospitalization are associated with 3% to 4% short-term mortality, and half of 
those hospitalized will be readmitted within 6 months (McCrory et al 2001). COPD is 
a major cause of morbidity and mortality worldwide, and the prevalence of the disease 
continues to rise (Sullivan et al 2000; Michaud et al 2001).
The main therapeutic options for the management of COPD are inhaled cortico-
steroids and bronchodilators. Inhaled corticosteroids signiﬁ  cantly reduce inﬂ  amma-
tory cells in the lungs, as well as systemic inﬂ  ammatory markers such as C-reactive 
protein, compared with placebo (Sin et al 2004; Gan et al 2005). However, there is 
some evidence that corticosteroids have no antiinﬂ  ammatory effects in COPD patients 
who are still smoking (Van Overveld et al 2006). The use of systemic corticosteroids 
in acute COPD exacerbations have been shown to improve lung function and reduce 
hospital stays and treatment failures (Wood-Baker et al 2001; Niewoehner 2002; 
Singh et al 2002). Outpatient treatment with systemic corticosteroids can improve International Journal of COPD 2007:2(1)  12
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symptoms and reduce the relapse rate (Aaron et al 2003). 
Meta-analyses have shown that long-term treatment with 
inhaled corticosteroids reduce the rate of COPD exacerbations 
by 30% and slow the progression of airway function decline (van 
Grunsven et al 1999; Alsaeedi et al 2002; Sutherland et al 2003; 
Salpeter and Buckley 2006). One meta-analysis of randomized 
controlled trials found a 25% reduction in all-cause mortality for 
inhaled corticosteroids compared with placebo (Sin et al 2005). 
However, pooled data from another meta-analysis did not show a 
reduction in respiratory or total mortality compared with placebo 
(Salpeter and Buckley 2006). 
The two types of bronchodilators, β-agonists and an-
ticholinergics, are generally considered to be equivalent 
choices in the treatment of COPD (Pauwels et al 2001; 
Celli and MacNee 2004; NCCC 2004). Many trials of 
these agents have concentrated on short-term physiologi-
cal endpoints, such as the forced expiratory volume at 1 
second (FEV1), quality of life, or symptoms. Anticholin-
ergics have been shown to have equal or superior efficacy 
as β-agonists in the improvement of lung function param-
eters (Karpel 1991; Rennard et al 1996; McCrory and 
Brown 2001; Sin et al 2003; Tashkin and Cooper 2004). 
However, surveys show that prescriptions for β-agonists 
are two times more common than anticholinergics in the 
UK and Europe, and ten times more common in the US 
(Ramsey 2000; Rudolf 2000; Roche et al 2001). 
This review summarizes the effect of β-agonists and 
anticholinergics on severe exacerbations and mortality, 
compared with placebo and with each other. The effects of 
inhaled corticosteroids on these outcomes are also evaluated. 
The results of two meta-analyses are presented (Salpeter and 
Buckley 2006; Salpeter, Buckley, Salpeter 2006) that pooled 
long-term randomized placebo-controlled trials of anticholin-
ergic or β-agonist use and evaluated COPD hospitalizations, 
respiratory mortality, and total mortality. Of note, after these 
meta-analyses were published it was revealed that data from 
one of the included trials was also reported in another trial 
(Brusasco et al 2006). We now provide the analysis with the 
duplicated data excluded. Information on the trials included 
in the meta-analysis is shown in Table 1. 
Anticholinergic bronchodilators
Anticholinergic bronchodilators include the short-acting 
ipratropium and oxtropium (not available in the US), and 
the long-acting tiotropium that has been recently introduced 
to the market (Barnes 2004). They work by inhibiting bron-
choconstriction as well as mucus secretion, and have been 
shown in clinical trials to reduce symptoms and exacerba-
tions, without the development of tolerance to their effects 
over time (Ashutosh and Lang 1984; Tashkin et al 1986; 
van Schayck et al 1990; Rennard et al 1996; Donohue et al 
2003; Barnes 2004). 
Anticholinergics compared with placebo 
The pooled results of 9 randomized placebo-controlled tri-
als (Table 1) that ranged from three months to ﬁ  ve years 
in duration (Salpeter, Buckley, Salpeter 2006) showed that 
anticholinergics reduced the risk of COPD hospitalizations 
by 30% and reduced respiratory deaths by 70%, compared 
with placebo (Figure 1). No signiﬁ  cant effect on total mor-
tality was seen (Salpeter and Buckley 2006). It is estimated 
that 58% of the participants were also taking concomitant 
inhaled corticosteroids.
Long-acting compared with short-acting 
anticholinergics
When trials that compared the long-acting tiotropium with the 
short-acting ipratropium were pooled together, tiotropium was 
associated with 40% less severe exacerbations than ipratropium 
(Barr et al 2005; Salpeter and Buckley 2006). A cost-effective 
analysis that was funded by Boehringer Ingelheim found that 
the mean healthcare costs for tiotropium, including medications 
and hospital visits, was slightly higher than with ipratropium 
(Oostenbrink et al 2004). However the beneﬁ  t of reducing 
hospitalizations was considered cost-effective. Tiotropium has 
also been shown to prevent the decline in trough FEV1 values, 
compared with placebo, over the course of one year (Casaburi 
et al 2000, 2002; FDA 2002; Barr et al 2005).
β-agonist bronchodilators
β-agonist bronchodilators work by relaxing bronchial 
smooth muscle, and have been shown to be effective in 
the short-term relief of COPD symptoms (Sestini et al 
2002). However, β-agonists have adverse cardiovascular 
effects and increase the risk of adverse cardiac events 
by over two-fold compared with placebo (Salpeter et al 
2004). This risk may be highest in patients with COPD 
and concomitant heart disease. In addition, significant 
tolerance to the respiratory effects of β-agonists develops 
with long-term use (Donohue et al 2003). 
Controversy has raged over the past 50 years concerning 
the safety of β-agonists in asthma and COPD (Lipworth 1992; 
Fahy and Boushey 1995; Taylor et al 1996). Regular β-agonist 
use in reactive airway disease results in tolerance to the drug’s 
bronchodilator and bronchoprotective effects, and is associated 
with poorer disease control (Sears et al 1990; Salpeter et al International Journal of COPD 2007:2(1)  13
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Table 1 Included studies in COPD meta-analysis
Study year  Number (n)   Active intervention  Concomitant
Duration (months)      corticosteroid use (%)
Anthonisen 2002  3923  Ipratropium   Not stated
60
Boyd 1997  674  Salmeterol  65
4
Brusasco 2003  1207  Tiotropium  Not stated
6   Salmeterol
Calverley 2003  511  Formoterol with and without  50
12   budesonide
Casaburi 2000  470  Tiotropium  Not stated
3
Casaburi 2002  921  Tiotropium  50
12
Colice 1996  223  Ipratropium  48
3   Albuterol
Combivent 1997  430  Ipratropium  Not stated
3    Albuterol and combination
Cook 2001  124  All on ipratropium with and  100
3   without  albuterol
Friedman 1999  709  Ipratropium  45
3    Albuterol and combination 
Mahler 2002  341  Salmeterol with and without  49
6   ﬂ  uticasone
Niewoehner 2005  1829  Tiotropium  70
6
Rennard 2001  273  Salmeterol Ipratropium  Not stated
3
Rossi 2002  645  Formoterol  48
12
Spiriva NDA (FDA 2002)  921  Tiotropium  Not stated
12
Szafranski 2003  406  Formoterol with and without   27
12   budesonide
Taylor 2001  507  Ipratropium  Not stated
3
Wadbo 2002  183  Ipratropium  Not stated
3   Formoterol 
Abbreviations: COPD, chronic obstructive pulmonary disease.
2004). A recent meta-analysis pooled results from 19 asthma 
trials with 33,826 participants and found that the long-acting 
β-agonists salmeterol and formoterol increased asthma hospi-
talizations, life-threatening asthma attacks, and asthma deaths 
by two-fold to four-fold, compared with placebo (Nelson et al 
2006; Salpeter, Buckley, Ormiston, et al 2006). Statistically 
signiﬁ  cant increases in asthma hospitalizations were seen for 
salmeterol and formoterol, and for children and adults. It was 
recently questioned whether the long-acting β-agonists should 
be taken off the market (FDA 2005).
β-agonists compared with placebo
The pooled results of 9 randomized-placebo controlled 
trials (Table 1) lasting from three to 12 months (Salpeter and 
Buckley 2006; Salpeter, Buckley, Salpeter 2006) showed 
that β-agonist use increased respiratory deaths by over two-
fold compared with placebo, without signiﬁ  cantly affecting 
hospitalizations or total mortality (Figure 2). It was estimated 
that 56% of the participants were on concomitant inhaled 
corticosteroids.
β-agonists compared with anticholinergics
Seven trials directly compared β-agonists with anticholin-
ergics in COPD (Table 1) and reported on hospitalizations 
or deaths (Salpeter and Buckley 2006; Salpeter, Buckley, 
Salpeter 2006). β-agonist use was associated with a two-fold 
increased risk for hospitalizations and a ﬁ  ve-fold increased 
risk for total mortality compared with anticholinergic use International Journal of COPD 2007:2(1)  14
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(Figure 3). Four additional trials evaluated the combination 
of anticholinergics and β-agonists (Table 1); pooled results 
found that the combination was not better than anticholinergic 
use alone on these long-term clinical outcomes (Salpeter and 
Buckley 2006). 
β-agonists compared with inhaled 
corticosteroids
Only three trials (Table 1) directly compared β-agonists 
with inhaled corticosteroids (Salpeter and Buckley 2006). 
Pooled results found that β-agonists were associated with 
a two-fold increased risk for total mortality compared with 
corticosteroids, with marginal signiﬁ  cance. 
One meta-analysis has evaluated combined corticosteroid 
and long-acting β-agonist treatment compared with placebo 
and either modality alone (Nannini et al 2004). Combina-
tion treatment reduced severe COPD exacerbations by 25% 
compared with placebo and by 22% compared with β-agonist 
alone. However, the combination treatment had no signiﬁ  cant 
effect on severe exacerbations compared with corticosteroid 
alone. Recently, an additional trial that lasted three years 
have been performed, but the results have not been presented 
(GlaxoSmithKline 2006). Preliminary results show that 
combined treatment reduced total mortality compared with 
placebo, but the results compared with inhaled corticosteroids 
alone and β-agonist alone are not available at present.
Figure 1 Effect of anticholinergics compared with placebo on COPD hospitalizations, respiratory deaths and total deaths.
Abbreviations: CI, conﬁ  dence internal; COPD, chronic obstructive pulmonary disease; NDA, new drug application.
Study Year Relative Risk
95% CI
Anticholinergics and hospitalization
Anticholinergics and respiratory deaths
Anticholinergics and total deaths
Brusasco 2003
Brusasco 2003
Brusasco 2003
Casaburi 2002
Niewoehner 2005
Niewoehner 2005
Taylor 2001
Wadbo 2002
Subtotal 
Subtotal 
Total events:
Total events:
Subtotal 
Total events:
121/2307 (Anticholinergic), 158/1874 (Placebo)
Spiriva NDA (FDA) 2002
Spiriva NDA (FDA) 2002
2/1866 (Anticholinergic), 10/1682 (Placebo)
92/4794 (Anticholinergic), 83/4340 (Placebo)
Anthonisen 2002
Casaburi 2000
Casaburi 2002
Niewoehner 2005
Rennard 2001
0.01 0.1 1 10 100
Favors Anticholinergic Favors Placebo
0.6 [0.3, 1.2]
0.6 [0.4, 0.9]
0.7 [0.5, 1.0]
0.7 [0.3, 2.1]
0.4 [0.1, 1.0]
0.3 [0.01, 8.1]
0.3 [0.07, 0.9]
0.3 [0.1, 1.4]
0.1 [0.01, 2.8]
1.2 [0.8, 1.8]
1.2 [0.6, 2.1]
1.0 [0.8, 1.4]
0.2 [0.02, 1.7]
0.3 [0.01, 7.9]
0.7 [0.2, 1.9]
0.7 [0.2, 1.9]
2.1 [0.08, 50.2]
0.7 [0.6, 0.9]International Journal of COPD 2007:2(1)  15
Bronchodilators in COPD
Summary
The main therapeutic options in the treatment of COPD have 
been bronchodilators in combination with inhaled cortico-
steroid. Guidelines presently state that both bronchodilators, 
anticholinergics and β-agonists, are equivalent choices for use 
in COPD, while in practice β-agonists are prescribed 2–10 times 
more often than anticholinergics. This systematic review has 
summarized the available data on long-term clinical outcomes 
associated with β-agonist and anticholinergic bronchodilators in 
COPD. Anticholinergic inhalers reduce COPD hospitalizations 
by 30% and respiratory deaths by 70% compared with placebo, 
while β-agonists increase respiratory mortality by over two-
fold compared with placebo. When compared with each other, 
β-agonists are associated with a two-fold increased risk for COPD 
hospitalization and a ﬁ  ve-fold increased risk for total mortality 
compared with anticholinergics. When β-agonists are added to 
anticholinergics or corticosteroids, there was no improvement 
in long-term clinical outcomes. 
This meta-analysis has several limitations. Meta-analytic 
results can be uncertain when the numbers of events per study 
are small, as is the case with respiratory deaths. Another limita-
tion is that most of the studies did not report deaths as a primary 
outcome, so the ascertainment of cause of death may be uncertain. 
It is unfortunate that there was not enough information to evaluate 
the protective effect of concomitant inhaled corticosteroids on the 
adverse effects of β-agonists. Furthermore, it was not possible to 
perform subgroup analysis to compare the differences in results 
between long-acting and short-acting β-agonists, or between the 
two long-acting agents, salmeterol and formoterol. Despite these 
limitations, this pooled analysis provides valuable information 
on the comparative effects of anticholinergics and β-agonists on 
clinical outcomes in COPD. 
These results indicate that anticholinergics are superior 
to β-agonists in improving long-term clinical outcomes, and 
that guidelines should be changed so that anticholinergics are 
the bronchodilator of choice in COPD. Tiotropium is more 
Study Year Relative Risk
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4.7 [0.3, 86.3]
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1.2 [0.7, 2.0]
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0.01 0.1 1 10 100
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Figure 2 Effect of β-agonists compared with placebo on COPD hospitalizations, respiratory deaths and total deaths.
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effective than ipratropium for long-term clinical outcomes, but 
at a slightly greater cost. We provide evidence that β-agonists 
may actually increase respiratory mortality by over two-fold 
compared with placebo. More studies are needed to evaluate 
the long-term clinical beneﬁ  t of the long-acting β-agonists, 
salmeterol and formoterol, in combination with inhaled cor-
ticosteroids, compared with the long-acting anticholinergic 
agent, tiotropium, combined with inhaled corticosteroids.
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